Department of Digital Communication, Soochow University, Soochow, China.
Eur Rev Med Pharmacol Sci. 2020 Dec;24(23):12545-12557. doi: 10.26355/eurrev_202012_24052.
Scientific research is an essential necessity for the prevention and control of COVID-19. Accelerated paper-sharing makes it possible to explore the responses of scientific communities of different countries and their research focus. This is achieved by examining relevant publications during the early stage of the pandemic. This paper explores a timely research assessment on COVID-19 among China, USA, and EU.
Papers indexed in PubMed and published from December 30, 2019, to March 11, 2020, were selected. Papers from China, USA, and EU were assessed by calculating the significance of items in the co-occurrence exported from VOSviewer.
The results showed that Chinese studies focus more on clinical manifestations, while USA and EU focus on experimental research. Furthermore, US research is more geared toward detection techniques and mathematical models, China focuses more on monitoring the epidemic situation, and EU engages in both.
This paper argues that the above distinctions are caused by differences in the stages of epidemic development, researchers' experience bases for formulating measures, traditions within the different medical cultures, and the distinction between "information" and "knowledge".
科学研究是 COVID-19 防控的必要手段。加快论文共享使得探索不同国家科学界的应对措施及其研究重点成为可能,这可以通过在大流行早期阶段检查相关出版物来实现。本文探讨了中国、美国和欧盟在 COVID-19 方面的及时研究评估。
选择了 2019 年 12 月 30 日至 2020 年 3 月 11 日在 PubMed 中索引并发表的论文。通过计算从 Vosviewer 导出的共现项目的显著性,对来自中国、美国和欧盟的论文进行评估。
结果表明,中国的研究更侧重于临床表现,而美国和欧盟则侧重于实验研究。此外,美国的研究更多地集中在检测技术和数学模型上,中国更多地关注疫情监测,而欧盟则两者兼顾。
本文认为,上述差异是由疫情发展阶段的不同、研究人员制定措施的经验基础、不同医学文化内部的传统以及“信息”和“知识”的区别造成的。